Skip to main content
. 2024 Oct 24;24:1307. doi: 10.1186/s12885-024-12841-2

Fig. 2.

Fig. 2

Kaplan-Meier plots of the median OS based on investigator’s assessment in group A (A), group B (B), group C (C) and group E (D). CAN, canakinumab; CARBO, carboplatin; CI, confidence interval; CIS, cisplatin; GEM, gemcitabine; OS, overall survival; PAC, paclitaxel; PEM, pemetrexed; SPARTA, spartalizumab